Cannara Biotech secures cultivation licence for Farnham Facility


Cannara Biotech, a Canadian cannabis company, has secured cultivation licence from Health Canada for 170,000 sq. ft. phase 1 of its Farnham Facility in Québec.

The Farnham Facility will produce indoor cannabis and cannabis-infused products targeting the Canadian and global markets.

Cannara Biotech expects to start cultivation immediately with a first harvest to occur in Q2 2020.

See also  Jordan Company divests DuBois Chemicals assets to Altas Partners

The licenced area is part of a larger 625,000 sq. ft. multipurpose and modern cannabis production facility.

Phase 1 of the Farnham Facility includes a designated space for the extraction and processing of cannabis and will create about 100 local jobs. The annual cultivation capacity of the first phase of the Farnham Facility is estimated at up to 20,000 kg per year.

See also  Wipro inaugurates Wipro-AWS Launch Pad Center in Toronto

Barry Laxer – COO of Cannara Biotech (Quebec) said: “After many months of diligent preparation, today’s milestone will allow us to start cultivation immediately and to advance our goal of becoming the premiere grower of cannabis in Québec and in due course, the rest of Canada.

“All of us would like to thank our construction team for delivering a state-of-the-art facility, along with the invaluable community support we have received. With a well-funded balance sheet, financially Cannara begins this next phase of our growth with strength and durable fundamentals.”

Cannara Biotech secures cultivation licence for Farnham Facility

Cannara Biotech secures cultivation licence for Farnham Facility. Photo courtesy of Rex Medlen from Pixabay.

Share This